Free tool
FAERS Monitor: Idacio
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming BLA 761255 or its brand name (Idacio, Adalimumab-Aacf). Reports on generic versions are filed under their own applications.
Reports
335
Serious
270
81% of reports
Hospitalization
163
Death reported
2
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- diarrhoea32
- psoriatic arthropathy32
- abdominal pain20
- drug ineffective19
- haematochezia18
- off label use18
- injection site pain15
- arthralgia14
- fatigue13
- vomiting13
- crohn^s disease12
- frequent bowel movements12
- influenza like illness12
- nasopharyngitis12
- product dose omission issue12
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2020 | 1 |
| 2021 | 4 |
| 2022 | 4 |
| 2023 | 34 |
| 2024 | 73 |
| 2025 | 129 |
| 2026 | 90 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,824 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| psoriatic arthropathySignal | 32 | 49.5 | 35.6 | 1,475 |
| frequent bowel movementsSignal | 12 | 27.9 | 16.0 | 285 |
| haematocheziaSignal | 18 | 20.5 | 13.1 | 315 |
| influenza like illnessSignal | 12 | 9.2 | 5.3 | 80 |
| abdominal painSignal | 20 | 5.4 | 3.5 | 68 |
| nasopharyngitisSignal | 12 | 4.1 | 2.3 | 25 |
| diarrhoeaSignal | 32 | 3.1 | 2.2 | 45 |
| injection site painSignal | 15 | 3.1 | 1.9 | 19 |
| product dose omission issueSignal | 12 | 2.6 | 1.5 | 10 |
| arthralgiaSignal | 14 | 2.1 | 1.3 | 7 |
| vomiting | 13 | 1.7 | 1.0 | 3 |
| off label use | 18 | 1.3 | 0.8 | 1 |
| fatigue | 13 | 1.0 | 0.6 | 0 |
| drug ineffective | 19 | 0.9 | 0.6 | 0 |
| crohn^s disease | 12 | 0.0 | 0.0 | 692,628 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.